Multi-phase Modulators for Dermal Fibrotic Disorders
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for dermal wound healing often result in undesirable scar formation due to improper modulation of the complex array of growth factors and cytokines involved in the healing process, making it challenging to effectively control fibrotic tissue formation across multiple phases of wound healing.
Innovation Solution
The use of multi-phase modulators, such as multikinase inhibitors (e.g., axitinib, nintedanib, sorafenib, sunitinib, lenvatinib) and soluble guanylate cyclase stimulators (e.g., riociguat), which interfere with multiple kinase-mediated signaling pathways to modulate exuberant activities in various phases of wound healing, thereby preventing or alleviating aberrant fibrotic tissue formations.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional treatments for dermal wound healing are used, then wound healing process is initiated, but undesirable scar formation and excessive fibrosis occur
Solution Approach 1:
The treatment approach segments the wound healing process into distinct phases (hemostasis, inflammation, proliferation, maturation) and applies phase-specific modulators to control the activity of growth factors and cytokines at each stage, preventing excessive fibrosis while maintaining effective wound healing
Solution Approach 2:
The invention changes the concentration and timing parameters of growth factors and cytokines during different wound healing phases by administering specific modulators (such as TGF-β inhibitors during proliferation phase) to prevent scar formation while preserving necessary healing functions
2Reliability
If multiple growth factors and cytokines are involved in wound healing, then comprehensive tissue repair is achieved, but controlling fibrotic tissue formation becomes challenging
Solution Approach 1:
The invention employs multi-functional modulators that can target multiple growth factor pathways simultaneously (such as agents that inhibit both TGF-β and PDGF signaling), simplifying the treatment approach while maintaining control over complex fibrotic processes
Solution Approach 2:
The invention introduces intermediary substances (such as soluble receptors or decoy molecules) that mediate the interaction between growth factors and their receptors, providing a controllable mechanism to regulate fibrotic tissue formation without directly interfering with all signaling pathways
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
These compounds effectively reduce neovascularization and fibrosis, as demonstrated by reduced TGF-β1 mRNA expression and histopathologic evaluations, indicating their potential in remedying undesired scar formation by controlling fibrotic tissue formation across multiple phases of wound healing.
Implementation Method 1
a soluble guanylate cyclase (SGC) stimulator can stimulate the activity of an SGC, leading to the formation of cyclic GMP (cGMP), which is a second messenger in various signal transduction pathways
Implementation Method 2
compounds of the invention include agents that can interfere with multiple phases (multiple targets) of wound healing processes. These agents will be referred to as 'multi-phase modulators' or 'multi-target modulators.' The 'multi-phase modulators' or 'multi-target modulators' may include multikinase inhibitors that can inhibit multiple kinases
Data Source
AI summary
A method for preventing and/or modulating formation of a dermal fibrotic disorder includes administering a therapeutically effective amount of a multi-phase modulator to a subject in need thereof. The multi-phase modulator is selected from the group consisting of axitinib, nintedanib, sorafenib, sunitinib, lenvatinib, panatinib, pazopanib, regorafenib, and riociguat. The dermal fibrotic disorder is acne scars, skin scars such as keloids and hypertrophic scars, wrinkles, cellulite and dermal neoplastic fibrosis, scarring alopecia, various vasculopathy, vasculitis, burn wound healing, diabetic foot syndrome, scleroderma, arthrofibrosis, peyronie's disease, dupuytren's contracture, or adhesive capsulitis.